相关实验视频
Updated: Sep 20, 2025

Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
针对胃肠道扩散型大B细胞淋巴瘤的部位和阶段适应的治疗策略
Yu Yagi1, Yusuke Kanemasa1, Yuki Sasaki1
1Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
胃肠扩散性大B细胞淋巴瘤 (GI-DLBCL) 的生存率与非GI-DLBCL相似. 特定于部位和阶段的治疗可能会改善GI-DLBCL患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 胃肠病学 胃肠病学
背景情况:
- 胃肠扩散性大B细胞淋巴瘤 (GI-DLBCL) 的治疗方法各不相同,最佳治疗策略也在讨论中.
- 了解特定于GI-DLBCL的预后因素和生存结果对于完善治疗方法至关重要.
研究的目的:
- 为了比较GI-DLBCL与非GI-DLBCL的生存结果.
- 分析疾病阶段对胃和肠道DLBCL存活率的影响.
- 评估局部性GI-DLBCL的治疗疗效和相关风险.
主要方法:
- 701名DLBCL患者 (2004-2024) 的回顾性分析,包括160名GI-DLBCL患者.
- 在GI-DLBCL和非GI-DLBCL队列之间的基线特征和生存率的比较.
- 根据疾病阶段对胃和肠道DLBCL的子组分析.
主要成果:
- 在GI-DLBCL和非GI-DLBCL组之间,整体存活率 (OS) 没有显著差异.
- 胃和肠道DLBCL的高级疾病与较差的OS有关.
- 用化疗治疗的局部胃DLBCL具有更高的二次癌症风险;经过手术和化疗的局部肠道DLBCL显示出有利的生存状况.
结论:
- 胃肠道DLBCL的生存结果与非胃肠道DLBCL相似.
- 建议采用特定于位点和阶段的治疗策略,以潜在地提高GI-DLBCL的生存益处.
更多相关视频
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Treatment Resistant Cancers